Fusion PharmaceuticalsÂ Inc (FUSN)

Name: Fusion PharmaceuticalsÂ Inc (FUSN) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Fusion PharmaceuticalsÂ Inc (FUSN)

Stock Card

$21.55

$0.00 (0.00%)

As on 04-Jun-2024 16:00EDT

Market cap

$1,833 Mln

Revenue (TTM)

$36 Mln

P/E Ratio

P/B Ratio

8.1

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Fusion PharmaceuticalsÂ Inc (FUSN) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 21.55 High: 21.55

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-42 Mln
ROE

-0.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-18.6
Debt to Equity

0.2
Book Value

$--
EPS

$-1.5
Face value

--
Shares outstanding

85,060,000

7 Years Aggregate

CFO

$-290.27 Mln

EBITDA

$-332.34 Mln

Net Profit

$-375.99 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Fusion PharmaceuticalsÂ Inc (FUSN)	124.2	0.5	79.7	339.8	37.3	--	--
BSE Sensex^*	-9.4	-2.5	3.2	-4.8	5.5	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 04-Jun-2024 | *As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2023	2022	2021
Fusion PharmaceuticalsÂ Inc (FUSN)	205.1	-24.5	-64.5
S&P Small-Cap 600	13.9	-17.4	25.3
BSE Sensex	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Fusion PharmaceuticalsÂ Inc (FUSN)

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical... trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada. As of June 4, 2024, Fusion Pharmaceuticals Inc. operates as a subsidiary of AstraZeneca AB. Read more

Founder, CEO & Director

Dr. John F. Valliant Ph.D.
Founder, CEO & Director

Dr. John F. Valliant Ph.D.
Headquarters

Hamilton, ON
Website

https://www.fusionpharma.com

FAQs for Fusion PharmaceuticalsÂ Inc (FUSN)

What is the current share price of Fusion PharmaceuticalsÂ Inc (FUSN) Today?

The share price of Fusion PharmaceuticalsÂ Inc (FUSN) is $21.55 (NASDAQ) as of 04-Jun-2024 16:00 EDT. Fusion PharmaceuticalsÂ Inc (FUSN) has given a return of 37.28% in the last 3 years.

What is the current PB & PE ratio of Fusion PharmaceuticalsÂ Inc (FUSN)?

Since, TTM earnings of Fusion PharmaceuticalsÂ Inc (FUSN) is negative, P/E ratio is not available.
The P/B ratio of Fusion PharmaceuticalsÂ Inc (FUSN) is 8.13 times as on 16-Jul-2024, a 68 premium to its peers’ median range of 4.83 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	-6.68	2.85
2022	-1.58	0.85
2021	-2.21	0.77
2020	-3.30	0.88
2019	--	--

What is the 52 Week High and Low of Fusion PharmaceuticalsÂ Inc (FUSN)?

The 52-week high and low of Fusion PharmaceuticalsÂ Inc (FUSN) are Rs -- and Rs -- as of 04-Sep-2026.

What is the market cap of Fusion PharmaceuticalsÂ Inc (FUSN)?

Fusion PharmaceuticalsÂ Inc (FUSN) has a market capitalisation of $ 1,833 Mln as on 16-Jul-2024. As per SEBI classification, it is a Small Cap company.

Should I invest in Fusion PharmaceuticalsÂ Inc (FUSN)?

Before investing in Fusion PharmaceuticalsÂ Inc (FUSN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.